Targeting PD-1 variants for treatment of cancer

A method of treating a solid tumor;

• melanoma;
• renal cell carcinoma;
• non small-cell lung cancer;
• bladder cancer;
• Hodgkin's lymphoma;
• or gastric cancer in a human by targeting PD-1 in the human, the method comprising administering an antibody or antibody fragment to the human, wherein the antibody or antibody fragment specifically binds a PD-1 encoded by a PD-1 nucleotide sequence comprising a SNP selected from the group consisting of:
• rs7568402;
• rs28699177;
• rs28542728;
• rs118117097;
• rs28570544;
• rs118027315;
• rs191919871;
• rs6707556;
• rs142909968;
• rs36084323;
• rs10204225;
• rs11568821;
• rs2227981;
• and rs2227982;
• wherein the antibody or antibody fragment comprises a human gamma-4 heavy chain constant region that comprises an amino acid selected from the group consisting of:
• a Leu at position 189 shown in SEQ ID NO:
• 73 and an Arg at position 289 shown in SEQ ID NO:
• 73;
• and
• wherein said human comprises
• (i) an IGHG4*01 human heavy chain constant region gene segment, or the human expresses antibodies comprising human gamma-4 heavy chain constant regions comprising said selected amino acid;
• and
• (ii) a PD-1 nucleotide sequence comprising said selected SNP.